Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Mar 3:2022:9374895.
doi: 10.1155/2022/9374895. eCollection 2022.

Protective Effect and Possible Mechanisms of Tripterygium Glycosides in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis

Zhou Lin  1 , Mangmang Chen  1 , Xuewu Chen  1 , Jiaru Chen  1 , Wei Zhang  1
Affiliations
Meta-Analysis

Protective Effect and Possible Mechanisms of Tripterygium Glycosides in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis

Zhou Lin et al. Oxid Med Cell Longev. .

Abstract

Objective: The safety and efficacy of Tripterygium glycosides (TG) were assessed for ankylosing spondylitis (AS) in accordance with the existing literatures.

Materials and methods: Electronic literature was searched from Chinese VIP databases, Cochrane Library, Chinese Biomedical Literature Database, Wanfang Web of Science, EMBASE, Chinese National Knowledge Infrastructure, and the PubMed for the studies with the publication from the beginning to December 2021. Randomized controlled trials (RCTs) were included only. The major variables of result comprised erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Spinal Pain Visual Analog Score (SP-VAS), Bath Ankylosing Spondylitis Functional Index (BASFI), and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Moreover, the secondary variables of result covered the overall clinical effective rate following the adverse drug reaction (ADR). We carried out the meta-analysis with the use of STATA 12.0 and RevMan 5.3. We used GRADE pro3.6.1 software to assess the quality of evidence.

Results: In general, we covered 15 randomized controlled trials with the focus of 1186 patients. As proven by our meta-analysis, TG as adjuvant therapy or monotherapy decreased the BASDAI, BASFI, SP-VAS, serum CRP, and ESR than control in patients suffering from AS. Additionally, TG treatment visibly improved the overall effective rate in AS. Nevertheless, TG was not found to significantly increase the rate of ADR in contrast to the control.

Conclusion: As indicated by our result, TG may be an option to treat AS. In this paper, we recommended strict trials with high quality and large samples sizes for confirming the finding here.

PubMed Disclaimer

Conflict of interest statement

The authors disclose that this study was conducted without any commercial or financial relationships that could be construed as a prospective conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of study selection.
Figure 2
Figure 2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figure 3
Figure 3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figure 4
Figure 4
Forest plot of BASDAI: (a) TG versus control and (b) TG plus control versus control.
Figure 5
Figure 5
Meta-regression analysis of BASDAI. (a) Sample size. (b) Publication year. (c) Age. (d) Course of treatment.
Figure 6
Figure 6
Forest plot of BASFI: (a) TG versus control and (b) TG plus control versus control.
Figure 7
Figure 7
Forest plot of SP-VAS: (a) TG versus control and (b) TG plus control versus control.
Figure 8
Figure 8
Forest plot of CRP: (a) TG versus control and (b) TG plus control versus control.
Figure 9
Figure 9
Forest plot of ESR: (a) TG versus control and (b) TG plus control versus control.
Figure 10
Figure 10
Forest plot of ER: (a) TG versus control and (b) TG plus control versus control.
Figure 11
Figure 11
Forest plot of ADR.
Figure 12
Figure 12
Begg's test and Egger's test of ADR.
Figure 13
Figure 13
Sensitivity analysis for BASDAI (a), BASFI (b), CRP (c), ESR (d), ADR (e), and ER (f).
See this image and copyright information in PMC

References

    1. Rolle A. S., Zimmermann B., Poon S. H. Etanercept-induced Henoch-Schönlein purpura in a patient with ankylosing spondylitis. Journal of Clinical Rheumatology . 2013;19(2):90–93. doi: 10.1097/RHU.0b013e3182863027. - DOI - PubMed
    1. Braun J., Sieper J. Ankylosing spondylitis. The Lancet . 2007;369(9570):1379–1390. doi: 10.1016/S0140-6736(07)60635-7. - DOI - PubMed
    1. Li H., Guo F., Luo Y. C., Zhu J. P., Wang J. L. Efficacy of Tripterygium glycosides tablet in treating ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. Clinical Rheumatology . 2015;34(11):1831–1838. doi: 10.1007/s10067-015-3043-6. - DOI - PubMed
    1. de Winter J. J., van Mens L. J., van der Heijde D., Landewe R., Baeten D. L. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Research & Therapy . 2016;18(1):p. 196. doi: 10.1186/s13075-016-1093-z. - DOI - PMC - PubMed
    1. Shen T. C., Lin C. L., Wei C. C., et al. The risk of asthma in patients with ankylosing spondylitis: a population-based cohort study. PLoS One . 2015;10(2, article e0116608) doi: 10.1371/journal.pone.0116608. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources